The women’s oncology market is experiencing significant growth potential, yet challenges in funding, innovation, and patient access persist, according to a recent PwC report. The analysis highlights women-specific cancers, such as breast, ovarian, endometrial, cervical, vulvar, and vaginal cancers, which collectively account for over 400,000 annual diagnoses in the U.S. alone. The global market, currently valued at $65–75 billion, is expected to expand to $100–110 billion by 2030, driven by advancements in therapeutics, diagnostics, and care delivery models.
While breast cancer has attracted substantial investment, gynecologic cancers remain underfunded. Data from 2025 reveals that ovarian cancer research received approximately $43,000 per death from the National Institutes of Health, compared to nearly $70,000 for breast cancer. The report underscores opportunities across the patient care continuum, including early risk assessment, expedited diagnoses, precision treatments, and enhanced long-term management, emphasizing the need to address systemic gaps at every stage.
Pharmaceuticals dominate the market, comprising nearly 70% of its value, attributed to high disease prevalence, favorable reimbursement structures, and scalable therapeutic innovations. Targeted therapies are increasingly replacing or supplementing conventional chemotherapy, enabling earlier and more personalized interventions. Additionally, evolving care delivery models present investment opportunities, particularly as younger demographics face rising cancer risks and survivorship gains traction as a priority.
Early detection remains a critical unmet need, especially for gynecologic cancers. Emerging solutions such as liquid biopsies, AI-driven diagnostic tools, mobile screening initiatives, and at-home testing are identified as pivotal for improving diagnostic timelines and accessibility. The report notes that private funding for women-specific cancers has been robust, with over $6.5 billion invested across nearly 400 deals between 2020 and 2025, with devices and diagnostics leading in transaction volume.
The findings highlight the importance of sustained investment in accelerating scientific progress. Decades of research and commercial funding in breast cancer have yielded measurable outcomes, offering a blueprint for replicating success in gynecologic cancers. Stakeholders are urged to prioritize strategic initiatives: pharmaceutical firms should leverage AI for biomarker discovery in gynecologic cancers, providers must develop longitudinal care frameworks, and payers and employers are encouraged to broaden coverage for evidence-based early detection protocols.